<DOC>
	<DOCNO>NCT02487459</DOCNO>
	<brief_summary>This open-label , non-randomized study evaluate safety two planned infusion BPX-501 T cell partially mismatch , relate ( haploidentical ) HSCT adult hematologic malignancy .</brief_summary>
	<brief_title>Safety Study Gene Modified Donor T-Cells Adults With Advanced Hematologic Malignancies</brief_title>
	<detailed_description>The objective evaluate safety two planned infusion BPX-501 partially mismatch , related HSCT post-transplant cyclophosphamide evaluate safety efficacy treatment dimerizer drug , rimiducid ( AP1903 ) , subject receive BPX-501 uncontrolled GvHD . Assuming toxicity , enrollment proceed sequentially initial 9 patient ( follow 3+3 design ) , follow 100 day , prior enrol subsequent 31 patient . Toxicity may increase number initial group patient ) . As multiple dose level may administer among first 9 ( ) patient , toxicity assess cohort maximum tolerate dose ( MTD ) . Stopping Rules ( Phase II portion study ) : - &gt; 20 % patient experience Grade III IV acute GVHD attributable BPX-501 T cell non-responsive AP1903 infusion . - Grade IV reaction related infusion BPX-501 AP1903 . - Death related BPX-501 AP1903 infusion . The Medical Monitoring committee review data investigator determine whether proceed implement change protocol BPX-501 contains genetically modify donor T cell inducible safety switch iCasp9 suicide gene . In event acute GvHD , administration rimiducid dimerizes activate caspase 9 ; activates downstream caspase , obligate cellular apoptosis within 24 hour .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent 2 . Patients one lifethreatening hematological malignancy : Acute lymphocytic leukemia ( ALL ) CR1 highrisk feature include adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL gene rearrangement ; great 1 cycle achiever remission persistent MRD ; ALL second great remission without MRD . Acute myeloid leukemia ( AML ) CR1 highrisk feature define : Greater 1 cycle induction therapy require achieve remission ; Preceding myelodysplastic syndrome ( MDS ) myeloproliferative disease ; Presence FLT3 mutation internal tandem duplication ; FAB M6 M7 classification ; Adverse cytogenetics , 5 , del 5q , 7 , del7q , abnormality involve 3q , 9q , 11q , 20q , 21q , 17 , +8 [ &gt; 3 abnormality ] ; AML second great remission , primary induction failure patient relapsed disease ; Advanced chronic myeloid leukemia ( CML ) progress blast phase accelerate phase need transplant HLA match donor ; MDS IPSS intermediate2 higher therapyrelated MDS.Hodgkin lymphoma NonHodgkin lymphoma ( NHL ) : relapse disease remission duration less 1 year , relapse previous autologous transplant , failure achieve CR chemotherapy . 3 . Age ≥ 18 year ≤ 65 year 4 . Deemed eligible allogeneic stem cell transplantation 5 . Lack suitable conventional donor ( i.e . 8/8 related unrelated donor ) presence rapidly progressive disease permit time identify unrelated donor 6 . HLA type perform high resolution ( allele level ) HLAA , B , Cw , DRBl loci A minimum genotypic identical haplotype match 4/8 require The donor recipient must identical , determine high resolution typing , least one allele follow genetic locus : HLAA , HLAB , HLACw , HLA DRB1 7 . Subjects adequate organ function measure : Cardiac : Left ventricular ejection fraction rest must &gt; 45 % Pulmonary : FEV 1 , FVC , DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; O2 saturation &gt; 92 % room air Hepatic : Direct bilirubin ≤ 3 x upper limit normal ( ULN ) , AST/ALT ≤ 5 x ULN Renal : Serum creatinine within normal range age creatinine clearance , recommend GFR ≥ 50 mL/min/1.73m2 8 . Performance status : Karnofsky ≥ 80 % Subjects meeting follow criterion NOT eligible study : 1 . HLA 8/8 allele match ( HLAA , B , Cw , DRBl ) relate unrelated donor able donate ; 2 . Autologous hematopoietic stem cell transplant ≤ 3 month prior enrollment ; 3 . Prior allogeneic transplantation ; 4 . Active CNS involvement malignant cell ( less 2 month condition ) ; 5 . Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) ; PI final arbiter criterion ; 6 . Positive HIV serology viral RNA ( ≥ Grade III per CTCAE criterion ) ; 7 . Pregnancy ( positive serum urine βHCG test ) breastfeeding ; 8 . Fertile men woman unwilling use effective form birth control abstinence year transplantation ; 9 . Bovine product allergy . 10 . Severe obesity ( patient 's weight &gt; /= 1.5x donor weight ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>non-hodgkin lymphoma</keyword>
	<keyword>hodgkin lymphoma</keyword>
</DOC>